New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
19:09 EDTDRTX, MDR, MDCO, AMRN, VRNT, ARTX, CBSTOn The Fly: After Hours Movers
HIGHER: Durata Therapeutics (DRTX), up 5.4% after an FDA Committee voted in favor of its Dalvance injection for the treatment of adult patients with acute bacterial skin and skin structure infections caused by certain bacteria... Amarin (AMRN), up 8.8% after announcing a co-promotion agreement with Kowa Pharmaceuticals America for its Vascepa capsules in the U.S... Verint Systems (VRNT), up 10% after reporting earnings that beat expectations and providing a fiscal year outlook that also topped estimates. LOWER: The Medicines Company (MDCO), down 14.3% after Durata and Cubist Pharmaceuticals (CBST) each received positive votes from FDA panels for bacteria treatments that could compete with its Oritavancin. Cubist (CBST), which confirmed the FDA panel vote intraday, saw shares gain $3.05, or 4.35%, to close at $73.15 for the session... Arotech (ARTX), down 12.5% after reporting fiscal year earnings and revenue that disappointed... McDermott (MDR), down 2.8% after filing to sell 10M tangible equity units and, in a separate release, saying that its first quarter results may differ "substantially" from the company's current expectation.
News For DRTX;MDR;MDCO;AMRN;VRNT;ARTX;CBST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 20, 2014
09:22 EDTCBSTOn The Fly: Pre-market Movers
Subscribe for More Information
07:32 EDTCBSTCubist names Perez CEO to succeed Bonney
Subscribe for More Information
07:30 EDTCBSTCubist names Perez CEO
06:56 EDTCBSTShire reopens acquistion talks with NPS Pharmaceuticals, Cubist, Telegraph says
Subscribe for More Information
October 16, 2014
08:08 EDTAMRNAmarin sees cash and cash equivalents of $135.4M at September 30
Subscribe for More Information
October 15, 2014
10:23 EDTAMRNAmarin management to meet with Oppenheimer
Meeting to be held on the West Coast on October 22 hosted by Oppenheimer.
10:02 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:54 EDTDRTXDurata Therapeutics downgraded to Neutral from Buy at Roth Capital
Subscribe for More Information
October 14, 2014
11:23 EDTCBSTBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
10:01 EDTDRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:30 EDTVRNTVerint Systems checks show good deal momentum, says FBR Capital
Subscribe for More Information
07:10 EDTDRTXDurata Therapeutics downgraded to Neutral from Outperform at Credit Suisse
Durata Therapeutics (DRTX ) is being acquired by Actavis (ACT) for $23 per share and $5 in contingent value rights and Credit Suisse does not believe a higher bid will emerge.
October 13, 2014
07:25 EDTMDCOEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
October 10, 2014
13:45 EDTDRTXDurata Therapeutics announces new data for dalbavancin
Subscribe for More Information
10:01 EDTMDROn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: 2U (TWOU) initiated with an Outperform at Pacific Crest... Bloomin' Brands (BLMN) initiated with an Outperform at BMO Capital... Brinker (EAT) initiated with a Market Perform at BMO Capital... Buffalo Wild Wings (BWLD) initiated with an Outperform at BMO Capital... Chipotle (CMG) initiated with a Market Perform at BMO Capital... Chuy's (CHUY) initiated with a Market Perform at BMO Capital... Darden (DRI) initiated with a Market Perform at BMO Capital... EMC (EMC) initiated with a Buy at Jefferies... EPR Properties (EPR) initiated with a Buy at BofA/Merrill... HP (HPQ) initiated with a Hold at Jefferies... IBM (IBM) initiated with an Underperform at Jefferies... McDermott (MDR) initiated with an In-Line at Imperial Capital... NetApp (NTAP) initiated with a Hold at Jefferies... New Residential (NRZ) initiated with a Neutral at Piper Jaffray... Nimble Storage (NMBL) initiated with a Buy at Jefferies... Noodles & Company (NDLS) initiated with an Outperform at BMO Capital... PDC Energy (PDCE) initiated with an Overweight at Stephens... Panera Bread (PNRA) initiated with a Market Perform at BMO Capital... Pioneer Natural (PXD) initiated with an Outperform at Imperial Capital... Resource America (REXI) initiated with a Buy at MLV & Co.... Rex Energy (REXX) initiated with an Overweight at Stephens... Seagate (STX) initiated with a Buy at Jefferies... Silicon Motion (SIMO) initiated with a Buy at Brean Capital... Texas Roadhouse (TXRH) initiated with a Market Perform at BMO Capital... W.P. Carey (WPC) initiated with a Neutral at BofA/Merrill... Wayfair (W) initiated with a Buy at Janney Capital...Western Digital (WDC) initiated with a Buy at Jefferies... Yelp (YELP) initiated with a Buy at Sterne Agee.
07:14 EDTMDCOThe Medicines Co's Q3 Angiomax estimate lowered at Credit Suisse
Subscribe for More Information
05:57 EDTMDRStocks with implied volatility movement; RSH MDR
Stocks with implied volatility movement; RadioShack (RSH) 245, McDermott (MDR) 76 according to iVolatility.
05:28 EDTMDRMcDermott initiated with an In-Line at Imperial Capital
Target $5.
October 9, 2014
16:57 EDTMDCOThe Medicines Co. announces journal publication of SOLO II phase 3 trial
The Medicines Company announced the publication of the results from the SOLO II phase 3 clinical trial of ORBACTIV, or oritavancin, for injection in the journal Clinical Infectious Diseases. ORBACTIV, is the first and only single dose intravenous antibiotic approved by FDA for the treatment of adults with Acute Bacterial Skin and Skin Structure Infections, or ABSSSI, caused or suspected to be caused by susceptible isolates of designated Gram-positive pathogens. The publication reported that a single, once only, 1200 mg intravenous dose of ORBACTIVTM was non-inferior to twice-daily intravenous dosing of vancomycin given for 7 to 10 days in patients with ABSSSI caused or suspected to be caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus. A single 1200 mg IV dose of ORBACTIV results in efficacy in ABSSSIs that is comparable and statistically non-inferior to vancomycin administered intravenously for 7-10 days. ORBACTIV had a safety profile comparable to vancomycin when monitored for up to 60 days following a single dose, with similar intensity, onset and duration of AEs.
October 8, 2014
07:18 EDTDRTX, CBSTInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use